# Journal of Clinical Psychiatry

## Subject Index to Volume 56: January 1995 Through December 1995


**Academic Highlights**
Current concepts in schizophrenia, part 1: pathophysiology research prompts assessment updates. May 214–225
Current concepts in schizophrenia, part 2: treatment issues and broadening options. June 269–280
Difficult differential diagnoses in psychiatry: the clinical use of SPECT. Nov 539–546
Highlights of the 1995 Psychiatry Global Medical Conference. Oct 488–499
Lithium: the present and the future. Jan 41–48
Seroquel: a putative atypical antipsychotic drug with serotonin- and dopamine-receptor antagonist properties: preclinical and early clinical trials in schizophrenia. Sept 438–445
Treatment of social phobia and comorbid disorders. Aug 380–387

**Adinazolam**
Adinazolam-SR in panic disorder with agoraphobia: relationship of daily dose to efficacy. Carter, May 202–210

**Adolescents**
Valproic acid for dysphoric mania in a mentally retarded adolescent [letter]. Whittier, Dec 590–591

**Affective Disorder**
Body dysmorphic disorder: an obsessive-compulsive spectrum disorder, a form of affective spectrum disorder, or both? Phillips, Suppl 4, 41–52
Gender differences in outpatient research subjects with affective disorders: a comparison of descriptive variables. Rapaport, Feb 67–72
Risperidone in the treatment of affective illness and obsessive-compulsive disorder. Jacobsen, Sept 423–429

**Aggression**
Divalproex sodium in the treatment of aggressive behavior and dysphoria in patients with organic brain syndromes [letter]. Horne, Sept 430–431
Sertraline treatment of aggression in a developmentally disabled patient [letter]. Campbell, Mar 123–124

**Agitation**
Effect of carbamazepine on agitation in Alzheimer's inpatients refractory to neuroleptics. Lemke, Aug 354–357
Response of anxiety and agitation symptoms during nefazodone treatment of major depression. Fawcett, Suppl 6, 37–42

**Agoraphobia**
Adinazolam-SR in panic disorder with agoraphobia: relationship of daily dose to efficacy. Carter, May 202–210

**Agranulocytosis**
Filgrastim treatment of three patients with clozapine-induced agranulocytosis. Lamberti, June 256–259

**Akathisia**
Is there a rationale for iron supplementation in the treatment of akathisia? a review of the evidence. Gold R, Oct 476–483

**Alcohol and Alcoholism**
Acute effects of zolpidem, administered alone and with alcohol, on cognitive and psychomotor function. Wilkinson, July 309–318
Effect of naltrexone on human alcohol consumption. Swift, Suppl 7, 24–29
Genetic factors in alcohol self-administration. Froehlich, Suppl 7, 15–23
Integration of opioid antagonists and psychosocial therapy in the treatment of narcotic and alcohol dependence. O'Malley, Suppl 7, 30–38
Introduction: opioid involvement in alcohol dependence. Volpicelli, Suppl 7, 3–4
Naltrexone in the treatment of alcoholism: predicting response to naltrexone. Volpicelli, Suppl 7, 39–44
Opiates and alcohol self-administration in animals. Ulm, Suppl 7, 5–14
Sertraline treatment of comorbid posttraumatic stress disorder and alcohol dependence. Brady, Nov 502–505
Treating anxiety in patients with alcoholism. Nunes, Suppl 2, 3–9

**Alprazolam**
Possible serotonin syndrome following the combined administration of clomipramine and alprazolam [letter]. Cano-Muñoz, Mar 122

**Alzheimer's Disease**
Effect of carbamazepine on agitation in Alzheimer's inpatients refractory to neuroleptics. Lemke, Aug 354–357

**Amantadine**
Added amantadine may diminish tardive dyskinesia in patients requiring continued neuroleptics [letter]. Freudenreich, Apr 173
No difference in the effect of biperiden and amantadine on parkinsonian– and tardive dyskinesia–type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients. Silver, Apr 167–170; correction Sept 435

**Amitriptyline**
Double-blind comparison of Org 3770, amitriptyline, and placebo in major depression. Bremner, Nov 519–525

**Antidepressant Drugs**
Are patients who are intolerant to one serotonin selective reuptake inhibitor intolerant to another? Brown, Jan 30–34
Costs of antidepressant medications [letter]. Clark, Sept 432
Efficacy of fluoxetine combined with a heterocyclic antidepressant in treatment-resistant depression: a retrospective analysis. Zajecka, Aug 338–343
Introduction: compliance strategies to optimize antidepressant treatment outcomes. Kupfer, Suppl 1, 3
Just what is a "heterocyclic" antidepressant? [letter]. Jefferson, Sept 433
Minimizing and managing antidepressant side effects. McElroy, Suppl 2, 49–55
Prescribing trends of antidepressants in bipolar depression. Zarate, June 260–264

**Anxiety**
Anxiety symptom relief in depression treatment outcomes. Keller, Suppl 6, 22–29
Combined treatment approach to anxiety in the medically ill. Wise, Suppl 2, 14–19
Effects of substance use disorder on the clinical presentation of anxiety and depression in an outpatient psychiatric clinic. Tsuang, Dec 549–555
Management of comorbid anxiety and depression. Zajecka, Suppl 2, 10–13
Management of depression and anxiety in the elderly. Fernandez, Suppl 2, 20–29
Response of anxiety and agitation symptoms during nefazodone treatment of major depression. Fawcett, Suppl 6, 37–42
Treating anxiety in patients with alcoholism. Nunes, Suppl 2, 3–9

**Attention-Deficit/Hyperactivity Disorder**
Dual diagnosis of attention-deficit/hyperactivity disorder and substance abuse: case reports and literature review. Schubiner, Apr 146–150

**Bacillary Angiomatosis**
Bacillary angiomatosis: a treatable cause of acute psychiatric symptoms in human immunodeficiency virus infection. Baker, Apr 161–166

**Behavior Therapy**
Advances in behavioral-cognitive therapy of social phobia. Marks, Suppl 5, 25–31
Interim analysis clarification [letter]. Liebowitz; Greist reply, Sept 435

**Benztropine**
Delirium: an SSRI-benztropine adverse effect? [letter]. Rothschild; Nelson reply, Nov 537

**Biperiden**
No difference in the effect of biperiden and amantadine on parkinsonian– and tardive dyskinesia–type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients. Silver, Apr 167–170; correction Sept 435

**Bipolar Disorder**
Course of illness and maintenance treatments for patients with bipolar disorder. Solomon, Jan 5–13

Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: a case series. Madhusoodanan, Nov 514–518
Introduction: history of the development of valproate for treatment of bipolar disorder. Bowden, Suppl 3, 3–5
Medication algorithm for treatment of bipolar rapid cycling? Calabrese, Suppl 3, 11–18
Mixed or dysphoric manic states: psychopathology and treatment. Swann, Suppl 3, 6–10
Nimodipine treatment of rapid cycling bipolar disorder [letter]. Goodnick, July 330
Predictors of response to divalproex and lithium. Bowden, Suppl 3, 25–30
Prescribing trends of antidepressants in bipolar depression. Zarate, June 260–264
Relationship between substance abuse and bipolar disorder. Brady, Suppl 3, 19–24
Secondary mania: diagnosis and treatment. Evans, Suppl 3, 31–37
Sucralfate in bipolar patients with valproate intolerance [letter]. Blum, Sept 432
Valproate in the treatment of acute bipolar affective episodes complicated by substance abuse: a pilot study. Brady, Mar 118–121

**Blood Drug Levels**
Plasma clozapine levels and clinical benefit [letter]. Greenberg; Piscitelli reply, Nov 535–536
Serum clomipramine and metabolite levels in four nursing mother-infant pairs. Wisner, Jan 17–20

**Body Dysmorphic Disorder**
Body dysmorphic disorder: an obsessive-compulsive spectrum disorder, a form of affective spectrum disorder, or both? Phillips, Suppl 4, 41–52
Body dysmorphic disorder, pathological gambling, and sexual compulsions. Hollander, Suppl 4, 7–13
Trichotillomania, body dysmorphic disorder, and obsessive-compulsive disorder [letter]. Christenson, May 211

**Books Reviewed**
Benjamin LS: *Interpersonal Diagnosis and Treatment of Personality Disorders*. Allen, Jan 39
Bloch S, Hafner J, Harari E, Szmukler GI: *The Family in Clinical Psychiatry*. Scott, Dec 592
Buckman ES (ed): *The Handbook of Humor: Clinical Applications in Psychotherapy*. Weise, June 267
Cromwell RL, Snyder CR (eds): *Schizophrenia: Origins, Processes, Treatment and Outcome*. Gold DD Jr, Feb 84
Druss RG: *The Psychology of Illness*. Alarcon, Nov 538
Feldman MD, Ford CV: *Patient or Pretender*. Newhouse, Mar 125
Gacono CB, Meloy JR: *The Rorschach Assessment of Aggressive and Psychopathic Personalities*. Battle, Sept 436
Gaw AC (ed): *Culture, Ethnicity and Mental Illness*. Kennedy, Jan 40
Gill MM: *Psychoanalysis in Transition*. Allen, July 335
Gold JH, Severino SK: *Premenstrual Dysphoria: Myths and Realities*. Brown CS, May 213
Goode D: *A World Without Words: The Social Construction of Children Born Deaf and Blind*. Battle, Apr 174
Guttmacher LB: *Concise Guide to Psychopharmacology and Electroconvulsive Therapy*. Linder, Mar 125
Hunter ME: *Creative Scripts for Hypnotherapy*. Battle, Aug 379
Kennedy SH (ed): *Clinical Advances in Monoamine Oxidase Inhibitors*. Newhouse, Mar 125
Leonard BE: *Fundamentals of Psychopharmacology*. Newhouse, May 213
Mirkin MP (ed): *Women in Context: Toward a Feminist Reconstruction of Psychotherapy*. Surawicz, July 335
Murburg MM (ed): *Catecholamine Function in Posttraumatic Stress Disorder*. Newhouse, Apr 174
Perris C: *Cognitive Therapy With Schizophrenic Patients*. Gold DD Jr, June 267–268
Schorr JH (ed): *Certification, Recertification, and Lifetime Learning in Psychiatry*. Muñoz, Jan 40
Stoudemire A (ed): *Psychological Factors Affecting Medical Conditions*. Walker, Oct 487
Torrey EF: *Surviving Schizophrenia: A Manual for Families, Consumers and Providers, Third Edition*. Gold DD Jr, Sept 436–437
Wilkes TCR, Belsher G, Rush AJ, Frank E: *Cognitive Therapy for Depressed Adolescents*. Fristad, June 267
Winegar N, Bestline JL: *Marketing Mental Health Services to Managed Care*. Walker, Feb 84
Zerbe KJ: *The Body Betrayed—Women, Eating Disorders, and Treatment*. Rosenthal, Jan 39–40

**Borderline Personality Disorder**
Open trial of valproate in borderline personality disorder. Stein, Nov 506–510

**Brain**
Delusional misidentification of the self associated with nondominant cerebral pathology [letter]. Silva, Apr 171
Recurrent manic episode 10 years after arteriovenous malformation resection [letter]. Tatter, Feb 83

**Breastfeeding**
Breastfeeding and sertraline: a 24-hour analysis. Altshuler, June 243–245
Serum clomipramine and metabolite levels in four nursing mother-infant pairs. Wisner, Jan 17–20

**Bulimia Nervosa**
Comorbidity of axis I psychiatric disorders in bulimia. Brewerton, Feb 77–80

**Bupropion**
Bupropion: a review of its mechanism of antidepressant activity. Ascher, Sept 395–401
Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. Preskorn, Suppl 6, 12–21
Sexual function in patients taking bupropion sustained release [letter]. Segraves, Aug 374

**Buspirone**
High cost of buspirone [letter]. Modell; Gelenberg reply, Aug 375–376
Use of fluoxetine and buspirone for treatment-refractory depersonalization disorder [letter]. Abbas, Oct 484

**Cannabidiol**
Antipsychotic effect of cannabidiol [letter]. Zuardi, Oct 485–486

**Carbamazepine**
Addition of monoamine oxidase inhibitors to carbamazepine: preliminary evidence of safety and antidepressant efficacy in treatment-resistant depression. Ketter, Oct 471–475
Carbamazepine-induced hyponatremia resolved with doxycycline [letter]. Boutros, Aug 377–378
Effect of carbamazepine on agitation in Alzheimer's inpatients refractory to neuroleptics. Lemke, Aug 354–357

**Cardiac Function**
Cardiovascular safety in depressed patients: focus on venlafaxine. Feighner, Dec 574–579
Electrocardiographic screening in psychiatric patients. Hollister, Jan 26–29

**Catatonia**
Fatal pulmonary embolism in the catatonic syndrome: two case reports and a literature review. McCall, Jan 21–25
Late-onset Tay-Sachs disease presenting as catatonic schizophrenia: diagnostic and treatment issues. Rosebush, Aug 347–353

**Children**
Estimation of the association between desipramine and the risk for sudden death in 5- to 14-year-old children. Biederman, Mar 87–93
Panic-phobic patients and developmental trauma. David, Mar 113–117

**Cholecystitis**
Valproate-associated pancreatitis and cholecystitis in six mentally retarded adults. Buzan, Nov 529–532

**Cholesterol**
Serum cholesterol levels and suicidality [letter]. Greenberg; Modai reply, Sept 434–435

**Clomipramine**
Disabling compulsions in 11 mentally retarded adults: an open trial of clomipramine SR. Barak, Oct 459–461
Double-blind comparison of clomipramine and desipramine in the treatment of developmental stuttering. Gordon, June 238–242
Double-blind crossover trial of clomipramine for rapid ejaculation in 15 couples. Althof, Sept 402–407
Fluoxetine-clomipramine interaction [letter]. Sternbach, Apr 171–172
Interim analysis clarification [letter]. Liebowitz; Greist reply, Sept 435
Possible serotonin syndrome following the combined administration of clomipramine and alprazolam [letter]. Cano-Muñoz, Mar 122
Serum clomipramine and metabolite levels in four nursing mother-infant pairs. Wisner, Jan 17–20

**Clonidine**
Clonidine treatment of excessive sweating [letter]. Feder, Jan 35

**Clozapine**
Clozapine and the development of salivary gland swelling: a case study. Vasile, Nov 511–513
Clozapine in severe mood disorders. Zarate, Sept 411–417
Effects of clozapine on smoking in chronic schizophrenic outpatients. George, Aug 344–346
Efficacy and adverse effects of clozapine in four elderly psychotic patients. Pitner, May 180–185
Filgrastim treatment of three patients with clozapine-induced agranulocytosis. Lamberti, June 256–259
Is clozapine a mood stabilizer? Zarate, Mar 108–112
Myoclonus in patients treated with clozapine: a case series. Bak, Sept 418–422
Photosensitivity to clozapine [letter]. Howanitz, Dec 589
Plasma clozapine levels and clinical benefit [letter]. Greenberg; Piscitelli reply, Nov 535–536
Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. Rich, Dec 556–559

**Cognitive Function**
Acute effects of zolpidem, administered alone and

with alcohol, on cognitive and psychomotor function. Wilkinson, July 309–318
**Cognitive Therapy**
Advances in behavioral-cognitive therapy of social phobia. Marks, Suppl 5, 25–31
**Comorbidity**
Comorbidity of axis I psychiatric disorders in bulimia. Brewerton, Feb 77–80
**Compliance**
Alliance not compliance: a philosophy of outpatient care. Frank, Suppl 1, 11–17
Compliance: definitions and key issues. Fawcett, Suppl 1, 4–10
Introduction: compliance strategies to optimize antidepressant treatment outcomes. Kupfer, Suppl 1, 3
Medication compliance in the elderly. Salzman, Suppl 1, 18–23
Psychotherapy, medication combinations, and compliance. Paykel, Suppl 1, 24–30
**Compulsive Buying**
Compulsive buying and depression [letter]. Lejoyeux, Jan 38
Kleptomania, compulsive buying, and binge-eating disorder. McElroy, Suppl 4, 14–27
**Corrections**
Norplant-associated major depression and panic disorder. Wagner, 1994 Nov 478–480; Correction, Mar 124
**Costs of Medical Care**
Costs of antidepressant medications [letter]. Clark, Sept 432
Editorial: threats and promises. Gelenberg, Oct 448–449
High cost of buspirone [letter]. Modell; Gelenberg reply, Aug 375–376
**Course of Illness**
Course of illness and maintenance treatments for patients with bipolar disorder. Solomon, Jan 5–13
**Cyproheptadine**
Adverse interaction of paroxetine and cyproheptadine [letter]. Christensen, Sept 433–434
**Delirium**
Delirium: an SSRI-benztropine adverse effect? [letter]. Rothschild; Nelson reply, Nov 537
**Delusions**
Fluoxetine-induced delusions in psychotic depression [letter]. Narayan, July 329
**Dementia**
Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: a case series. Madhusoodanan, Nov 514–518
**Depersonalization**
Depersonalization disorder and self-injurious behavior. Simeon, Suppl 4, 36–40
Use of fluoxetine and buspirone for treatment-refractory depersonalization disorder [letter]. Abbas, Oct 484
**Depression**
Addition of monoamine oxidase inhibitors to carbamazepine: preliminary evidence of safety and antidepressant efficacy in treatment-resistant depression. Ketter, Oct 471–475
Anxiety symptom relief in depression treatment outcomes. Keller, Suppl 6, 22–29
Bacillary angiomatosis: a treatable cause of acute psychiatric symptoms in human immunodeficiency virus infection. Baker, Apr 161–166
Cardiovascular safety in depressed patients: focus on venlafaxine. Feighner, Dec 574–579
Compulsive buying and depression [letter]. Lejoyeux, Jan 38
Depressive personality disorder [letter]. Sherman; Hirschfeld reply, June 266
Double-blind comparison of Org 3770, amitriptyline, and placebo in major depression. Bremner, Nov 519–525
Double-blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression. Bennie, June 229–237
Double-blind, placebo-controlled trial of two dose ranges of nefazodone in the treatment of depressed outpatients. Mendels, Suppl 6, 30–36
Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. Guelfi, Oct 450–458
Effect of ECT on mortality and clinical outcome in geriatric unipolar depression. Philibert, Sept 390–394
Effects of substance use disorder on the clinical presentation of anxiety and depression in an outpatient psychiatric clinic. Tsuang, Dec 549–555
Efficacy of fluoxetine combined with a heterocyclic antidepressant in treatment-resistant depression: a retrospective analysis. Zajecka, Aug 338–343
Fluoxetine-induced delusions in psychotic depression [letter]. Narayan, July 329
Hypothyroidism and hyperthyroidism in major depression revisited. Fava, May 186–192
Major depression and irritable bowel syndrome: is there a relationship? Masand, Aug 363–367
Major depression following myiasis with hypereosinophilic syndrome [letter]. Hampel, July 333–334
Management of comorbid anxiety and depression. Zajecka, Suppl 2, 10–13
Management of depression and anxiety in the elderly. Fernandez, Suppl 2, 20–29
New strategies in the treatment of depression in women. Pajer, Suppl 2, 30–37
Relapse in patients on long-term fluoxetine treatment: response to increased fluoxetine dose. Fava, Feb 52–55
Response of anxiety and agitation symptoms during nefazodone treatment of major depression. Fawcett, Suppl 6, 37–42
Role for stimulants in the treatment of depressive disorders [letter]. Moldawsky; Sabaawi reply, Aug 376–377
Subsyndromal symptomatic depression may include sleep disorders [letter]. Rank, July 329
Treatment of depression in patients with diabetes mellitus. Goodnick, Apr 128–136
Treatment of sleep disturbances in depressed patients. Neylan, Suppl 2, 56–61
**Desipramine**
Double-blind comparison of clomipramine and desipramine in the treatment of developmental stuttering. Gordon, June 238–242
Estimation of the association between desipramine and the risk for sudden death in 5- to 14-year-old children. Biederman, Mar 87–93
**Diabetes**
Treatment of depression in patients with diabetes mellitus. Goodnick, Apr 128–136
**Diagnosis**
Diagnosis of social phobia. Greist, Suppl 5, 5–12
Effects of race on diagnosis and disposition from a psychiatric emergency service. Strakowski, Mar 101–107
Late-onset Tay-Sachs disease presenting as catatonic schizophrenia: diagnostic and treatment issues. Rosebush, Aug 347–353
Rhinotillexomania: psychiatric disorder or habit? Jefferson, Feb 56–59
**Diet**
Monoamine oxidase inhibitor dietary restrictions: what are we asking patients to give up? Sweet, May 196–201
**Dopamine**
Treatment of sexual side effects with dopaminergic agents [letter]. Gitlin, Mar 124
**Dosage**
How much Haldol D does Larry really need? [letter]. Freudenreich, July 331–332
Relapse in patients on long-term fluoxetine treatment: response to increased fluoxetine dose. Fava, Feb 52–55
**Doxepin**
Doxepin withdrawal mania [letter]. Galynker, Mar 122–123
**Doxycycline**
Carbamazepine-induced hyponatremia resolved with doxycycline [letter]. Boutros, Aug 377–378
**Drug Administration Routes**
Haloperidol decanoate: injection site reactions [letter]. Maharaj, Apr 172–173
How much Haldol D does Larry really need? [letter]. Freudenreich, July 331–332
**Drug Interactions**
Adverse interaction of paroxetine and cyproheptadine [letter]. Christensen, Sept 433–434
Fluoxetine and sumatriptan: possibly a counterproductive combination [letter]. Szabo, Jan 37–38
Fluoxetine-clomipramine interaction [letter]. Sternbach, Apr 171–172
Paroxetine-molindone interaction [letter]. Malek-Ahmadi, Feb 82–83
**Drug Side Effects**
Clozapine and the development of salivary gland swelling: a case study. Vasile, Nov 511–513
Delirium: an SSRI-benztropine adverse effect? [letter]. Rothschild; Nelson reply, Nov 537
Fluoxetine and hemostatic function: a pilot study. Berk, Jan 14–16
Fluoxetine-induced delusions in psychotic depression [letter]. Narayan, July 329
Lithium tremor. Gelenberg, July 283–287
Minimizing and managing antidepressant side effects. McElroy, Suppl 2, 49–55
Photosensitivity reaction to fluoxetine [letter]. Gaufberg, Oct 486
Risperidone and neuroleptic malignant syndrome: a case report [letter]. Najara, Nov 534–535
Treatment of sexual side effects with dopaminergic agents [letter]. Gitlin, Mar 124
**Drugs, Psychotropic**
Commentary. Medication use during psychoanalysis: a survey. Michels, May 179
Medication use during psychoanalysis: a survey. Donovan, May 177–178
**Drug Therapy, Combination**
Factors predicting the use of multiple psychotropic medications. Nichol, Feb 60–66
Psychotherapy, medication combinations, and compliance. Paykel, Suppl 1, 24–30
**Drug Withdrawal Phenomena**
Methadone withdrawal psychosis. Levinson, Feb 73–76
**Dysphoria**
Divalproex sodium in the treatment of aggressive behavior and dysphoria in patients with organic brain syndromes [letter]. Horne, Sept 430–431
**Eating Disorders see also Bulimia**
Kleptomania, compulsive buying, and binge-eating disorder. McElroy, Suppl 4, 14–27

**ECT see Electroconvulsive Therapy**
**Elderly see also Geriatric Psychiatry**
Effect of ECT on mortality and clinical outcome in geriatric unipolar depression. Philibert, Sept 390–394
Efficacy and adverse effects of clozapine in four elderly psychotic patients. Pitner, May 180–185
Management of depression and anxiety in the elderly. Fernandez, Suppl 2, 20–29
Medication compliance in the elderly. Salzman, Suppl 1, 18–23
**Electrocardiogram**
Electrocardiographic screening in psychiatric patients. Hollister, Jan 26–29
**Electroconvulsive Therapy**
Carbon monoxide–related organic mood disorder successfully treated with ECT [letter]. Jerrett, July 332–333
ECT for OCD [letter]. Beale; Jenike reply, Feb 81–82
Effect of ECT on mortality and clinical outcome in geriatric unipolar depression. Philibert, Sept 390–394
Fatal pulmonary embolism in the catatonic syndrome: two case reports and a literature review. McCall, Jan 21–25
**Electroencephalography**
EEG abnormalities in patients with atypical panic attacks. Weilburg, Aug 358–362
**Emergency Psychiatry**
Effects of race on diagnosis and disposition from a psychiatric emergency service. Strakowski, Mar 101–107
**Erotomania**
Love without romance: the complexity of erotomanic delusions [letter]. Remington, Nov 533–534
**Extrapyramidal Side Effects**
Assessment of extrapyramidal symptoms during acute neuroleptic treatment. Mazure, Mar 94–100
No difference in the effect of biperiden and amantadine on parkinsonian– and tardive dyskinesia–type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients. Silver, Apr 167–170; correction Sept 435
**Filgrastim**
Filgrastim treatment of three patients with clozapine-induced agranulocytosis. Lamberti, June 256–259
**Fluoxetine**
Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. Preskorn, Suppl 6, 12–21
Double-blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression. Bennie, June 229–237
Double-blind, randomized study to provide safety information on switching fluoxetine-treated patients to paroxetine without an intervening washout period. Kreider, Apr 142–145
Efficacy of fluoxetine combined with a heterocyclic antidepressant in treatment-resistant depression: a retrospective analysis. Zajecka, Aug 338–343
Fluoxetine and hemostatic function: a pilot study. Berk, Jan 14–16
Fluoxetine and social phobia [letter]. Berk, Jan 36–37
Fluoxetine and sumatriptan: possibly a counterproductive combination [letter]. Szabo, Jan 37–38
Fluoxetine-clomipramine interaction [letter]. Sternbach, Apr 171–172
Fluoxetine-induced delusions in psychotic depression [letter]. Narayan, July 329
Fluoxetine treatment of compulsive masturbation in a schizophrenic patient [letter]. Kornreich, July 334
Photosensitivity reaction to fluoxetine [letter]. Gaufberg, Oct 486
Postmarketing surveillance by patient self-monitoring: preliminary data for sertraline versus fluoxetine. Fisher, July 288–296
Provide fluoxetine information vital to clinicians [letter]. Cohen JS, Dec 591
Relapse in patients on long-term fluoxetine treatment: response to increased fluoxetine dose. Fava, Feb 52–55
Use of fluoxetine and buspirone for treatment-refractory depersonalization disorder [letter]. Abbas, Oct 484
**Fluvoxamine**
Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases. McDougle, Nov 526–528
Severe myoclonus produced by fluvoxamine [letter]. Bauer, 589–590
**Gambling**
Body dysmorphic disorder, pathological gambling, and sexual compulsions. Hollander, Suppl 4, 7–13
**Gender see Sex Differences**
**Genetics**
Genetic factors in alcohol self-administration. Froehlich, Suppl 7, 15–23
**Geriatric Psychiatry**
Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: a case series. Madhusoodanan, Nov 514–518
**Gilles de la Tourette's Syndrome**
Suicide in Gilles de la Tourette's syndrome: report of two cases [letter]. Robertson, Aug 378
**Hair Pulling see Trichotillomania**
**Hallucinations**
Command hallucinations in outpatients with schizophrenia. Zisook, Oct 462–465
**Haloperidol**
Haloperidol decanoate: injection site reactions [letter]. Maharaj, Apr 172–173
How much Haldol D does Larry really need? [letter]. Freudenreich, July 331–332
**Health Care Reform**
Editorial: threats and promises. Gelenberg, Oct 448–449
Impact of health care reform on social phobia. Hirschfeld, Suppl 5, 13–17
**Hemostatic Function**
Fluoxetine and hemostatic function: a pilot study. Berk, Jan 14–16
**Hormone Replacement Therapy**
Hormone replacement therapy may reduce panic symptoms [letter]. Chung, Nov 533
**Human Immunodeficiency Virus**
Bacillary angiomatosis: a treatable cause of acute psychiatric symptoms in human immunodeficiency virus infection. Baker, Apr 161–166
**Hypereosinophilic Syndrome**
Major depression following myiasis with hypereosinophilic syndrome [letter]. Hampel, July 333–334
**Hyperthyroidism**
Hypothyroidism and hyperthyroidism in major depression revisited. Fava, May 186–192
**Hyponatremia**
Carbamazepine-induced hyponatremia resolved with doxycycline [letter]. Boutros, Aug 377–378
**Hypothyroidism**
Hypothyroidism and hyperthyroidism in major depression revisited. Fava, May 186–192
**Imipramine**
Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. Preskorn, Suppl 6, 12–21
**In Memoriam**
Robins, Eli (1921–1994). Murphy, June 228
**Injections**
Haloperidol decanoate: injection site reactions [letter]. Maharaj, Apr 172–173
**Inpatients**
Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. Guelfi, Oct 450–458
Effect of carbamazepine on agitation in Alzheimer's inpatients refractory to neuroleptics. Lemke, Aug 354–357
**Iron**
Is there a rationale for iron supplementation in the treatment of akathisia? a review of the evidence. Gold R, Oct 476–483
**Irritable Bowel Syndrome**
Major depression and irritable bowel syndrome: is there a relationship? Masand, Aug 363–367
***Journal of Clinical Psychiatry***
Duplicate publication [letter]. Gelenberg, Feb 81
**Kleptomania**
Kleptomania, compulsive buying, and binge-eating disorder. McElroy, Suppl 4, 14–27
**Lithium**
Further prospective evaluation of an equation to predict daily lithium dose. Terao, May 193–195
Lithium: the present and the future [ACADEMIC HIGHLIGHTS]. Jan 41–48
Lithium tremor. Gelenberg, July 283–287
Predictors of response to divalproex and lithium. Bowden, Suppl 3, 25–30
**Maintenance Treatment**
Course of illness and maintenance treatments for patients with bipolar disorder. Solomon, Jan 5–13
**Mania**
Doxepin withdrawal mania [letter]. Galynker, Mar 122–123
Mixed or dysphoric manic states: psychopathology and treatment. Swann, Suppl 3, 6–10
Recurrent manic episode 10 years after arteriovenous malformation resection [letter]. Tatter, Feb 83
Risperidone treatment of refractory acute mania [letter]. Goodnick, Sept 431–432
Secondary mania: diagnosis and treatment. Evans, Suppl 3, 31–37
Valproic acid for dysphoric mania in a mentally retarded adolescent [letter]. Whittier, Dec 590–591
**Medical Illness**
Combined treatment approach to anxiety in the medically ill. Wise, Suppl 2, 14–19
Medical histories and psychological profiles of middle-aged women with and without self-reported illness from environmental chemicals. Bell, Apr 151–160
**Medication see Drugs, Psychotropic**
**Melancholia see Depression**
**Men**
Sexual dysfunction in male schizophrenic patients. Aizenberg, Apr 137–141
**Mental Retardation**
Disabling compulsions in 11 mentally retarded

adults: an open trial of clomipramine SR. Barak, Oct 459–461
Sertraline treatment of aggression in developmentally disabled patient [letter]. Campbell, Mar 123–124
Valproate-associated pancreatitis and cholecystitis in six mentally retarded adults. Buzan, Nov 529–532
Valproic acid for dysphoric mania in a mentally retarded adolescent [letter]. Whittier, Dec 590–591
**Methadone**
Methadone withdrawal psychosis. Levinson, Feb 73–76
**Migraine**
Paroxetine as migraine prophylaxis [letter]. Black, July 330–331
**Misidentification Syndromes**
Delusional misidentification of the self associated with nondominant cerebral pathology [letter]. Silva, Apr 171
**Molindone**
Paroxetine-molindone interaction [letter]. Malek-Ahmadi, Feb 82–83
**Monoamine Oxidase Inhibitors**
Addition of monoamine oxidase inhibitors to carbamazepine: preliminary evidence of safety and antidepressant efficacy in treatment-resistant depression. Ketter, Oct 471–475
Monoamine oxidase inhibitor dietary restrictions: what are we asking patients to give up? Sweet, May 196–201
**Mood**
Carbon monoxide–related organic mood disorder successfully treated with ECT [letter]. Jerrett, July 332–333
Clozapine in severe mood disorders. Zarate, Sept 411–417
Is clozapine a mood stabilizer? Zarate, Mar 108–112
**Mortality**
Effect of ECT on mortality and clinical outcome in geriatric unipolar depression. Philibert, Sept 390–394
**Movement Disorders**
No difference in the effect of biperiden and amantadine on parkinsonian– and tardive dyskinesia–type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients. Silver, Apr 167–170; correction Sept 435
**Multiple Chemical Sensitivity**
Medical histories and psychological profiles of middle-aged women with and without self-reported illness from environmental chemicals. Bell, Apr 151–160
**Multiple Sclerosis**
Commentary: patients with multiple sclerosis presenting to psychiatric hospitals. Popkin, July 307–308
Patients with multiple sclerosis presenting to psychiatric hospitals. Pine, July 297–306
**Myiasis**
Major depression following myiasis with hypereosinophilic syndrome [letter]. Hampel, July 333–334
**Myoclonus**
Myoclonus in patients treated with clozapine: a case series. Bak, Sept 418–422
Severe myoclonus produced by fluvoxamine [letter]. Bauer, 589–590
**Naltrexone**
Effect of naltrexone on human alcohol consumption. Swift, Suppl 7, 24–29
Naltrexone in the treatment of alcoholism: predicting response to naltrexone. Volpicelli, Suppl 7, 39–44
**Nefazodone**
Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. Preskorn, Suppl 6, 12–21
Double-blind, placebo-controlled trial of two dose ranges of nefazodone in the treatment of depressed outpatients. Mendels, Suppl 6, 30–36
Nefazodone: aspects of efficacy. Rickels, Suppl 6, 43–46
Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug. Taylor, Suppl 6, 3–11
Response of anxiety and agitation symptoms during nefazodone treatment of major depression. Fawcett, Suppl 6, 37–42
**Neurochemistry**
Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug. Taylor, Suppl 6, 3–11
**Neuroleptic Drugs**
Added amantadine may diminish tardive dyskinesia in patients requiring continued neuroleptics [letter]. Freudenreich, Apr 173
Assessment of extrapyramidal symptoms during acute neuroleptic treatment. Mazure, Mar 94–100
Rabbit syndrome and tardive dyskinesia: two complications of chronic neuroleptic treatment [letter]. Schwartz, May 212
**Neuroleptic Malignant Syndrome**
Risperidone and neuroleptic malignant syndrome: a case report [letter]. Najara, Nov 534–535
**Neurologic Manifestations**
Commentary: patients with multiple sclerosis presenting to psychiatric hospitals. Popkin, July 307–308
Patients with multiple sclerosis presenting to psychiatric hospitals. Pine, July 297–306
Rabbit syndrome and tardive dyskinesia: two complications of chronic neuroleptic treatment [letter]. Schwartz, May 212
**Nimodipine**
Nimodipine treatment of rapid cycling bipolar disorder [letter]. Goodnick, July 330
**Obsessive-Compulsive Disorder**
Body dysmorphic disorder: an obsessive-compulsive spectrum disorder, a form of affective spectrum disorder, or both? Phillips, Suppl 4, 41–52
ECT for OCD [letter]. Beale; Jenike reply, Feb 81–82
Interim analysis clarification [letter]. Liebowitz; Greist reply, Sept 435
Introduction: obsessive-compulsive spectrum disorders. Hollander, Suppl 4, 3–6
Obsessive-compulsive spectrum disorders [letter]. Stein, June 265–266
Phenomenology of intentional repetitive behaviors in obsessive-compulsive disorder and Tourette's disorder. Miguel, June 246–255
Predictors of drug treatment response in obsessive-compulsive disorder. Ravizza, Aug 368–373
Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases. McDougle, Nov 526–528
Risperidone in the treatment of affective illness and obsessive-compulsive disorder. Jacobsen, Sept 423–429
Serum clomipramine and metabolite levels in four nursing mother-infant pairs. Wisner, Jan 17–20
Trichotillomania and obsessive-compulsive disorder. Stein, Suppl 4, 28–35
Trichotillomania, body dysmorphic disorder, and obsessive-compulsive disorder [letter]. Christenson, May 211
**Opiates**
Opiates and alcohol self-administration in animals. Ulm, Suppl 7, 5–14
**Opioid System**
Integration of opioid antagonists and psychosocial therapy in the treatment of narcotic and alcohol dependence. O'Malley, Suppl 7, 30–38
Introduction: opioid involvement in alcohol dependence. Volpicelli, Suppl 7, 3–4
**Org 3770**
Double-blind comparison of Org 3770, amitriptyline, and placebo in major depression. Bremner, Nov 519–525
**Organic Mental Disorders**
Carbon monoxide–related organic mood disorder successfully treated with ECT [letter]. Jerrett, July 332–333
Delusional misidentification of the self associated with nondominant cerebral pathology [letter]. Silva, Apr 171
Treatment of organic personality syndrome with low-dose trazodone [letter]. Tejera, Aug 374–375
**Outpatients**
Alliance not compliance: a philosophy of outpatient care. Frank, Suppl 1, 11–17
Command hallucinations in outpatients with schizophrenia. Zisook, Oct 462–465
Double-blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression. Bennie, June 229–237
Effects of clozapine on smoking in chronic schizophrenic outpatients. George, Aug 344–346
Effects of substance use disorder on the clinical presentation of anxiety and depression in an outpatient psychiatric clinic. Tsuang, Dec 549–555
Gender differences in outpatient research subjects with affective disorders: a comparison of descriptive variables. Rapaport, Feb 67–72
**Pancreatitis**
Valproate-associated pancreatitis and cholecystitis in six mentally retarded adults. Buzan, Nov 529–532
**Panic**
Adinazolam-SR in panic disorder with agoraphobia: relationship of daily dose to efficacy. Carter, May 202–210
EEG abnormalities in patients with atypical panic attacks. Weilburg, Aug 358–362
Hormone replacement therapy may reduce panic symptoms [letter]. Chung, Nov 533
Panic disorder and pregnancy [letter]. Benjamin; Sholomskas reply, Jan 36
Panic-phobic patients and developmental trauma. David, Mar 113–117
Venlafaxine treatment of panic disorder: a case series. Geracioti, Sept 408–410
**Parkinson's Disease**
Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. Rich, Dec 556–559
**Paroxetine**
Adverse interaction of paroxetine and cyproheptadine [letter]. Christensen, Sept 433–434
Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. Preskorn, Suppl 6, 12–21

Double-blind, randomized study to provide safety information on switching fluoxetine-treated patients to paroxetine without an intervening washout period. Kreider, Apr 142–145
Paroxetine as migraine prophylaxis [letter]. Black, July 330–331
Paroxetine-molindone interaction [letter]. Malek-Ahmadi, Feb 82–83
**Personality Disorder**
Depressive personality disorder [letter]. Sherman; Hirschfeld reply, June 266
Treatment of organic personality syndrome with low-dose trazodone [letter]. Tejera, Aug 374–375
**Pharmacology**
Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug. Taylor, Suppl 6, 3–11
**Pharmacotherapy**
Social phobia: a pharmacologic treatment overview. Jefferson, Suppl 5, 18–24
**Phobias see also specific phobias**
Fluoxetine and social phobia [letter]. Berk, Jan 36–37
Panic-phobic patients and developmental trauma. David, Mar 113–117
**Photosensitivity**
Photosensitivity reaction to fluoxetine [letter]. Gaufberg, Oct 486
Photosensitivity to clozapine [letter]. Howanitz, Dec 589
**Physician-Patient Relations**
Alliance not compliance: a philosophy of outpatient care. Frank, Suppl 1, 11–17
**Postmarketing Surveillance**
Postmarketing surveillance by patient self-monitoring: preliminary data for sertraline versus fluoxetine. Fisher, July 288–296
**Postpartum Disorders**
Serum clomipramine and metabolite levels in four nursing mother-infant pairs. Wisner, Jan 17–20
**Posttraumatic Stress Disorder**
Sertraline treatment of comorbid posttraumatic stress disorder and alcohol dependence. Brady, Nov 502–505
**Prediction**
Further prospective evaluation of an equation to predict daily lithium dose. Terao, May 193–195
Medication algorithm for treatment of bipolar rapid cycling? Calabrese, Suppl 3, 11–18
Naltrexone in the treatment of alcoholism: predicting response to naltrexone. Volpicelli, Suppl 7, 39–44
Predictors of drug treatment response in obsessive-compulsive disorder. Ravizza, Aug 368–373
Predictors of response to divalproex and lithium. Bowden, Suppl 3, 25–30
**Pregnancy**
Panic disorder and pregnancy [letter]. Benjamin; Sholomskas reply, Jan 36
**Prescribing Practices**
Prescribing trends of antidepressants in bipolar depression. Zarate, June 260–264
**Primary Care**
Factors predicting the use of multiple psychotropic medications. Nichol, Feb 60–66
**Psychiatry**
Highlights of the 1995 Psychiatry Global Medical Conference [ACADEMIC HIGHLIGHTS]. Oct 488–499
Serotonergic mechanisms and current and future psychiatric practice. Dubovsky, Suppl 2, 38–48
**Psychoanalysis**
Commentary. Medication use during psychoanalysis: a survey. Michels, May 179
Medication use during psychoanalysis: a survey. Donovan, May 177–178
**Psychomotor Function**
Acute effects of zolpidem, administered alone and with alcohol, on cognitive and psychomotor function. Wilkinson, July 309–318
**Psychopathology see also specific diagnoses**
Commentary: patients with multiple sclerosis presenting to psychiatric hospitals. Popkin, July 307–308
Patients with multiple sclerosis presenting to psychiatric hospitals. Pine, July 297–306
**Psychosis**
Bacillary angiomatosis: a treatable cause of acute psychiatric symptoms in human immunodeficiency virus infection. Baker, Apr 161–166
Efficacy and adverse effects of clozapine in four elderly psychotic patients. Pitner, May 180–185
Methadone withdrawal psychosis. Levinson, Feb 73–76
Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. Rich, Dec 556–559
**Psychosocial Therapy**
Integration of opioid antagonists and psychosocial therapy in the treatment of narcotic and alcohol dependence. O'Malley, Suppl 7, 30–38
**Psychotherapy**
Psychotherapy, medication combinations, and compliance. Paykel, Suppl 1, 24–30
**Psychotropic Drugs**
Factors predicting the use of multiple psychotropic medications. Nichol, Feb 60–66
Psychotropic medications and their effects on sexual function [letter]. Jefferson; Gitlin reply, Nov 536–537
**Pulmonary Embolism**
Fatal pulmonary embolism in the catatonic syndrome: two case reports and a literature review. McCall, Jan 21–25
**Rabbit Syndrome**
Rabbit syndrome and tardive dyskinesia: two complications of chronic neuroleptic treatment [letter]. Schwartz, May 212
**Race**
Effects of race on diagnosis and disposition from a psychiatric emergency service. Strakowski, Mar 101–107
**Rating Scales**
Personality traits in social phobia, I: comparisons with healthy controls. Fahlén, Dec 560–568
Personality traits in social phobia, II: changes during drug treatment. Fahlén, Dec 569–573
**Recurrence see Relapse**
**Relapse**
Relapse in patients on long-term fluoxetine treatment: response to increased fluoxetine dose. Fava, Feb 52–55
**Rhinotillexomania**
Rhinotillexomania: psychiatric disorder or habit? Jefferson, Feb 56–59
**Risperidone**
Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders. Keck, Oct 466–470
Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: a case series. Madhusoodanan, Nov 514–518
Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases. McDougle, Nov 526–528
Risperidone and neuroleptic malignant syndrome: a case report [letter]. Najara, Nov 534–535
Risperidone and tardive dyskinesia: a case report [letter]. Addington, Oct 484–485
Risperidone in the treatment of affective illness and obsessive-compulsive disorder. Jacobsen, Sept 423–429
Risperidone treatment of refractory acute mania [letter]. Goodnick, Sept 431–432
Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. Rich, Dec 556–559
**Safety**
Double-blind, randomized study to provide safety information on switching fluoxetine-treated patients to paroxetine without an intervening washout period. Kreider, Apr 142–145
**Salivary Glands**
Clozapine and the development of salivary gland swelling: a case study. Vasile, Nov 511–513
**Schizoaffective Disorder**
Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders. Keck, Oct 466–470
Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: a case series. Madhusoodanan, Nov 514–518
**Schizophrenia**
Antipsychotic effect of cannabidiol [letter]. Zuardi, Oct 485–486
Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders. Keck, Oct 466–470
Command hallucinations in outpatients with schizophrenia. Zisook, Oct 462–465
Current concepts in schizophrenia, part 1: pathophysiology research prompts assessment updates [ACADEMIC HIGHLIGHTS]. May 214–225
Current concepts in schizophrenia, part 2: treatment issues and broadening options [ACADEMIC HIGHLIGHTS]. June 269–280
Effects of clozapine on smoking in chronic schizophrenic outpatients. George, Aug 344–346
Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: a case series. Madhusoodanan, Nov 514–518
Fluoxetine treatment of compulsive masturbation in a schizophrenic patient [letter]. Kornreich, July 334
Late-onset Tay-Sachs disease presenting as catatonic schizophrenia: diagnostic and treatment issues. Rosebush, Aug 347–353
No difference in the effect of biperiden and amantadine on parkinsonian– and tardive dyskinesia–type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients. Silver, Apr 167–170; correction Sept 435
Sexual dysfunction in male schizophrenic patients. Aizenberg, Apr 137–141
**Self-Injurious Behavior**
Depersonalization disorder and self-injurious behavior. Simeon, Suppl 4, 36–40
Self-injurious behavior: pathophysiology and implications for treatment. Pies, Dec 580–588
**Sensory Effects**
Dose-related sensory distortions with zolpidem [letter]. Pies, Jan 35–36

**Seroquel**
Seroquel: a putative atypical antipsychotic drug with serotonin- and dopamine-receptor antagonist properties: preclinical and early clinical trials in schizophrenia [ACADEMIC HIGHLIGHTS]. Sept 438–445
**Serotonin**
Are patients who are intolerant to one serotonin selective reuptake inhibitor intolerant to another? Brown, Jan 30–34
Possible serotonin syndrome following the combined administration of clomipramine and alprazolam [letter]. Cano-Muñoz, Mar 122
Serotonergic mechanisms and current and future psychiatric practice. Dubovsky, Suppl 2, 38–48
**Sertraline**
Breastfeeding and sertraline: a 24-hour analysis. Altshuler, June 243–245
Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. Preskorn, Suppl 6, 12–21
Double-blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression. Bennie, June 229–237
Postmarketing surveillance by patient self-monitoring: preliminary data for sertraline versus fluoxetine. Fisher, July 288–296
Sertraline for premature ejaculation [letter]. Mendels; Wise reply, Dec 591
Sertraline treatment of aggression in a developmentally disabled patient [letter]. Campbell, Mar 123–124
Sertraline treatment of comorbid posttraumatic stress disorder and alcohol dependence. Brady, Nov 502–505
**Sex Differences**
Gender differences in outpatient research subjects with affective disorders: a comparison of descriptive variables. Rapaport, Feb 67–72
**Sexual Behavior**
Body dysmorphic disorder, pathological gambling, and sexual compulsions. Hollander, Suppl 4, 7–13
Fluoxetine treatment of compulsive masturbation in a schizophrenic patient [letter]. Kornreich, July 334
**Sexual Function**
Double-blind crossover trial of clomipramine for rapid ejaculation in 15 couples. Althof, Sept 402–407
Psychotropic medications and their effects on sexual function [letter]. Jefferson; Gitlin reply, Nov 536–537
Sertraline for premature ejaculation [letter]. Mendels; Wise reply, Dec 591
Sexual dysfunction in male schizophrenic patients. Aizenberg, Apr 137–141
Sexual function in patients taking bupropion sustained release [letter]. Segraves, Aug 374
Treatment of sexual side effects with dopaminergic agents [letter]. Gitlin, Mar 124
**Sleep**
Subsyndromal symptomatic depression may include sleep disorders [letter]. Rank, July 329
Treatment of sleep disturbances in depressed patients. Neylan, Suppl 2, 56–61
**Smoking**
Effects of clozapine on smoking in chronic schizophrenic outpatients. George, Aug 344–346
**Social Phobia**
Advances in behavioral-cognitive therapy of social phobia. Marks, Suppl 5, 25–31
Diagnosis of social phobia. Greist, Suppl 5, 5–12
Fluoxetine and social phobia [letter]. Berk, Jan 36–37
Impact of health care reform on social phobia. Hirschfeld, Suppl 5, 13–17
Introduction: unmasking social phobia in the clinical setting. Jefferson, Suppl 5, 3–4
Personality traits in social phobia, I: comparisons with healthy controls. Fahlén, Dec 560–568
Personality traits in social phobia, II: changes during drug treatment. Fahlén, Dec 569–573
Social phobia: a pharmacologic treatment overview. Jefferson, Suppl 5, 18–24
Treatment of social phobia and comorbid disorders [ACADEMIC HIGHLIGHTS]. Aug 380–387
**SPECT**
Difficult differential diagnoses in psychiatry: the clinical use of SPECT [ACADEMIC HIGHLIGHTS]. Nov 539–546
**Stimulants**
Role for stimulants in the treatment of depressive disorders [letter]. Moldawsky; Sabaawi reply, Aug 376–377
**Stuttering**
Double-blind comparison of clomipramine and desipramine in the treatment of developmental stuttering. Gordon, June 238–242
**Substance Abuse**
Dual diagnosis of attention-deficit/hyperactivity disorder and substance abuse: case reports and literature review. Schubiner, Apr 146–150
Effects of substance use disorder on the clinical presentation of anxiety and depression in an outpatient psychiatric clinic. Tsuang, Dec 549–555
Integration of opioid antagonists and psychosocial therapy in the treatment of narcotic and alcohol dependence. O'Malley, Suppl 7, 30–38
Relationship between substance abuse and bipolar disorder. Brady, Suppl 3, 19–24
Valproate in the treatment of acute bipolar affective episodes complicated by substance abuse: a pilot study. Brady, Mar 118–121
**Sucralfate**
Sucralfate in bipolar patients with valproate intolerance [letter]. Blum, Sept 432
**Sudden Death**
Estimation of the association between desipramine and the risk for sudden death in 5- to 14-year-old children. Biederman, Mar 87–93
**Suicide**
Serum cholesterol levels and suicidality [letter]. Greenberg; Modai reply, Sept 434–435
Suicide in Gilles de la Tourette's syndrome: report of two cases [letter]. Robertson, Aug 378
**Sumatriptan**
Fluoxetine and sumatriptan: possibly a counterproductive combination [letter]. Szabo, Jan 37–38
**Sweating**
Clonidine treatment of excessive sweating [letter]. Feder, Jan 35
**Tardive Dyskinesia**
Added amantadine may diminish tardive dyskinesia in patients requiring continued neuroleptics [letter]. Freudenreich, Apr 173
Rabbit syndrome and tardive dyskinesia: two complications of chronic neuroleptic treatment [letter]. Schwartz, May 212
Risperidone and tardive dyskinesia: a case report [letter]. Addington, Oct 484–485
**Tay-Sachs Disease**
Late-onset Tay-Sachs disease presenting as catatonic schizophrenia: diagnostic and treatment issues. Rosebush, Aug 347–353
**Tolerance**
Are patients who are intolerant to one serotonin selective reuptake inhibitor intolerant to another? Brown, Jan 30–34
**Tourette's Disorder**
Phenomenology of intentional repetitive behaviors in obsessive-compulsive disorder and Tourette's disorder. Miguel, June 246–255
**Trauma**
Panic-phobic patients and developmental trauma. David, Mar 113–117
**Trazodone**
Treatment of organic personality syndrome with low-dose trazodone [letter]. Tejera, Aug 374–375
**Tremor**
Lithium tremor. Gelenberg, July 283–287
**Trichotillomania**
Clinical profile, comorbidity, and treatment history in 123 hair pullers: a survey study. Cohen LJ, July 319–328
Trichotillomania and obsessive-compulsive disorder. Stein, Suppl 4, 28–35
Trichotillomania, body dysmorphic disorder, and obsessive-compulsive disorder [letter]. Christenson, May 211
**Valproate**
Divalproex sodium in the treatment of aggressive behavior and dysphoria in patients with organic brain syndromes [letter]. Horne, Sept 430–431
Introduction: history of the development of valproate for treatment of bipolar disorder. Bowden, Suppl 3, 3–5
Mixed or dysphoric manic states: psychopathology and treatment. Swann, Suppl 3, 6–10
Open trial of valproate in borderline personality disorder. Stein, Nov 506–510
Predictors of response to divalproex and lithium. Bowden, Suppl 3, 25–30
Sucralfate in bipolar patients with valproate intolerance [letter]. Blum, Sept 432
Valproate-associated pancreatitis and cholecystitis in six mentally retarded adults. Buzan, Nov 529–532
Valproate in the treatment of acute bipolar affective episodes complicated by substance abuse: a pilot study. Brady, Mar 118–121
Valproic acid for dysphoric mania in a mentally retarded adolescent [letter]. Whittier, Dec 590–591
**Venlafaxine**
Cardiovascular safety in depressed patients: focus on venlafaxine. Feighner, Dec 574–579
Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. Preskorn, Suppl 6, 12–21
Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. Guelfi, Oct 450–458
Venlafaxine treatment of panic disorder: a case series. Geracioti, Sept 408–410
**Women**
Medical histories and psychological profiles of middle-aged women with and without self-reported illness from environmental chemicals. Bell, Apr 151–160
New strategies in the treatment of depression in women. Pajer, Suppl 2, 30–37
**Zolpidem**
Acute effects of zolpidem, administered alone and with alcohol, on cognitive and psychomotor function. Wilkinson, July 309–318
Dose-related sensory distortions with zolpidem [letter]. Pies, Jan 35–36

# Journal of Clinical Psychiatry

## Author Index to Volume 56: January 1995 Through December 1995


**Abaza A see Madhusoodanan S**

**Abbas S, Chandra PS, Srivastava M.** Use of fluoxetine and buspirone for treatment-refractory depersonalization disorder [letter]. Oct 484

**Abrahzm ME see Fava M**

**Addington DE, Toews JA, Addington JM.** Risperidone and tardive dyskinesia: a case report [letter]. Oct 484–485

**Adès J see Lejoyeux M**

**Addington JM see Addington DE**

**Aizenberg D, Zemishlany Z, Dorfman-Etrog P, Weizman A.** Sexual dysfunction in male schizophrenic patients. Apr 137–141

**Alarcon RD.** Review of Druss RG: *The Psychology of Illness.* Nov 538

**Allen DM.** Review of Benjamin LS: *Interpersonal Diagnosis and Treatment of Personality Disorders.* Jan 39

**Allen DM.** Review of Gill MM: *Psychoanalysis in Transition.* July 335

**Allen SA see Malek-Ahmadi P**

**Alpert JE see Fava M**

**Althof SE, Levine SB, Corty EW, Risen CB, Stern EB, Kurit DM.** Double-blind crossover trial of clomipramine for rapid ejaculation in 15 couples. Sept 402–407

**Altshuler LL, Burt VK, McMullen M, Hendrick V.** Breastfeeding and sertraline: a 24-hour analysis. June 243–245

**Anton R see Brady KT**

**Anton SF see Fawcett J; Mendels J**

**Araujo L see Madhusoodanan S**

**Aronowitz B see Cohen LJ**

**Ascher JA, Cole JO, Colin J-N, Feighner JP, Ferris RM, Fibiger HC, Golden RN, Martin P, Potter WZ, Richelson E, Sulser F.** Bupropion: a review of its mechanism of antidepressant activity. Sept 395–401

**Baer L see Miguel EC**

**Bak TH, Bauer M, Schaub RT, Hellweg R, Reischies FM.** Myoclonus in patients treated with clozapine: a case series. Sept 418–422

**Baker J, Ruiz-Rodriguez R, Whitfeld M, Heon V, Berger TG.** Bacillary angiomatosis: a treatable cause of acute psychiatric symptoms in human immunodeficiency virus infection. Apr 161–166

**Baldessarini RJ see Zarate CA Jr**

**Balistreri TM see Keck PE Jr**

**Ballenger JC see Brady KT; Brewerton TD**

**Banov MD see Zarate CA Jr**

**Baraibar G see Zarate CA Jr**

**Barak Y, Ring A, Levy D, Granek I, Szor H, Elizur A.** Disabling compulsions in 11 mentally retarded adults: an open trial of clomipramine SR. Oct 459–461

**Barzega G see Ravizza L**

**Battle AO.** Review of Gacono CB, Meloy JR: *The Rorschach Assessment of Aggressive and Psychopathic Personalities.* Sept 436

**Battle AO.** Review of Goode D: *A World Without Words: The Social Construction of Children Born Deaf and Blind.* Apr 174

**Battle AO.** Review of Hunter ME: *Creative Scripts for Hypnotherapy.* Aug 379

**Bauer M.** Severe myoclonus produced by fluvoxamine [letter]. Dec 589–590

**Bauer M see Bak TH**

**Beale MD, Kellner CH, Pritchett JT, Burns CM.** ECT for OCD [letter with reply]. Feb 81

**Bell IR, Peterson JM, Schwartz GE.** Medical histories and psychological profiles of middle-aged women with and without self-reported illness from environmental chemicals. Apr 151–160

**Bellino S see Ravizza L**

**Bellnier TJ see Lamberti JS**

**Benjamin J, Benjamin M.** Panic disorder and pregnancy [letter with reply]. Jan 36

**Benjamin M see Benjamin J**

**Bennie EH, Mullin JM, Martindale JJ.** Double-blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression. June 229–237

**Berger TG see Baker J**

**Berk M.** Fluoxetine and social phobia [letter]. Jan 36–37

**Berk M, Jacobson BF, Hurly E.** Fluoxetine and hemostatic function: a pilot study. Jan 14–16

**Bhandary AN see Masand P**

**Biederman J, Thisted RA, Greenhill LL, Ryan ND.** Estimation of the association between desipramine and the risk for sudden death in 5- to 14-year-old children. Mar 87–93

**Black KJ, Sheline YI.** Paroxetine as migraine prophylaxis [letter]. July 330–331

**Blum LD.** Sucralfate in bipolar patients with valproate intolerance [letter]. Sept 432

**Bogetto F see Ravizza L**

**Boutros NN, Guerra BM, Votolato NA, Smith S.** Carbamazepine-induced hyponatremia resolved with doxycycline [letter]. Aug 377–378

**Bowden CL.** Predictors of response to divalproex and lithium. Suppl 3, 25–30

**Bowden CL, McElroy SL.** Introduction: history of the development of valproate for treatment of bipolar disorder. Suppl 3, 3–5

**Bowden CL see Silva JA**

**Bowers MB Jr see Mazure CM**

**Brady KT, Sonne SC.** Relationship between substance abuse and bipolar disorder. Suppl 3, 19–24

**Brady KT, Sonne SC, Anton R, Ballenger JC.** Valproate in the treatment of acute bipolar affective episodes complicated by substance abuse: a pilot study. Mar 118–121

**Brady KT, Sonne SC, Roberts JM.** Sertraline treatment of comorbid posttraumatic stress disorder and alcohol dependence. Nov 502–505

**Bremner JD.** Double-blind comparison of Org 3770, amitriptyline, and placebo in major depression. Nov 519–525

**Brenner R see Madhusoodanan S**

**Brewerton TD, Lydiard RB, Herzog DB, Brotman AW, O'Neil PM, Ballenger JC.** Comorbidity of axis I psychiatric disorders in bulimia nervosa. Feb 77–80

**Brotman AW see Brewerton TD**

**Brown CS.** Review of Gold JH, Severino SK: *Premenstrual Dysphoria: Myths and Realities.* May 213

**Brown EJ see Sweet RA**

**Brown WA, Harrison W.** Are patients who are intolerant to one serotonin selective reuptake inhibitor intolerant to another? Jan 30–34

**Bryant SG see Fisher S**

**Bubna CN see Segraves RT**

**Buki VMV see Goodnick PJ**

**Burns CM see Beale MD**

**Burt VK see Altshuler LL**

**Bushnell WD see Kreider MS**

**Buzan RD, Firestone D, Thomas M, Dubovsky SL.** Valproate-associated pancreatitis and cholecystitis in six mentally retarded adults. Nov 529–532

**Byerly MJ see Evans DL**

**Byrd D see Zisook S**

**Calabrese JR, Woyshville MJ.** Medication algorithm for treatment of bipolar rapid cycling? Suppl 3, 11–18

**Callahan JW see Rosebush PI**

**Campbell JJ III, Duffy JD.** Sertraline treatment of aggression in a developmentally disabled patient [letter]. Mar 123–124

**Cano-Muñoz JL, Montejo-Iglesias ML, Yañez-Saez RM, Gálvez-Borrero IM.** Possible serotonin syndrome following the combined administration of clomipramine and alprazolam [letter]. Mar 122

**Caroff SN see McCall WV**

**Carter CS, Fawcett J, Hertzman M, Papp LA, Jones W, Patterson WM, Swinson RP, Weise CC, Maddock RJ, Denahan AQ, Liebowitz M.** Adinazolam-SR in panic disorder with agoraphobia: relationship of daily dose to efficacy. May 202–210

**Carter RB see Taylor DP**

**Cellar JS see Mazure CM**

**Chandra PS see Abbas S**
**Charles E see Pine DS**
**Christensen RC.** Adverse interaction of paroxetine and cyproheptadine [letter]. Sept 433–434
**Christenson GA, Mackenzie TB.** Trichotillomania, body dysmorphic disorder, and obsessive-compulsive disorder [letter]. May 211
**Chung CK, Remington ND, Suh BY.** Estrogen replacement therapy may reduce panic symptoms [letter]. Nov 533
**Ciafre L see Sweet RA**
**Clark DB.** Costs of antidepressant medications [letter]. Sept 432
**Clarke JTR see Rosebush PI**
**Clay KL see Volpicelli JR**
**Coffey BJ see Miguel EC**
**Cohen JS.** Provide fluoxetine information vital to clinicians [letter]. Dec 591
**Cohen LJ, Stein DJ, Simeon D, Spadaccini E, Rosen J, Aronowitz B, Hollander E.** Clinical profile, comorbidity, and treatment history in 123 hair pullers: a survey study. July 319–328
**Cohen LJ see Stein DJ**
**Cole JO see Ascher JA; Zarate CA Jr**
**Colin J-N see Ascher JA**
**Cornelius JR see Sweet RA**
**Corty EW see Althof SE**
**Cotelingam GM see Gordon CT**
**Cowley D see Tsuang D**
**Crist A see Strakowski SM**
**David D, Giron A, Mellman TA.** Panic-phobic patients and developmental trauma. Mar 113–117
**Davies M see Pine DS**
**Denahan AQ see Carter CS**
**DePreist M see Keck PE Jr**
**Den Dulk A see Kornreich C**
**Donovan SJ, Roose SP.** Medication use during psychoanalysis: a survey. May 177–178
**Dorfman-Etrog P see Aizenberg D**
**Douglas CJ see Pine DS**
**Dube S see Sweet RA**
**Dubovsky SL, Thomas M.** Serotonergic mechanisms and current and future psychiatric practice. Suppl 2, 38–48
**Dubovsky SL see Buzan RD**
**Duffy JD see Campbell JJ III**
**Dunner DL see Tsuang D**
**Eapen V see Robertson MM**
**Eison AS see Taylor DP**
**Elizur A see Barak Y**
**Ellison JM see Gaufberg E**
**Enikeev ID see Najara JE**
**Epperson CN see McDougle CJ**
**Erdreich M see Schwartz M**
**Evans DL, Byerly MJ, Greer RA.** Secondary mania: diagnosis and treatment. Suppl 3, 31–37
**Fahlén T.** Personality traits in social phobia, I: comparisons with healthy controls. Dec 560–568
**Fahlén T.** Personality traits in social phobia, II: changes during drug treatment. Dec 569–573
**Fava M, Labbate LA, Abraham ME, Rosenbaum JF.** Hypothyroidism and hyperthyroidism in major depression revisited. May 186–192
**Fava M, Rappe SM, Pava JA, Nierenberg AA, Alpert JE, Rosenbaum JF.** Relapse in patients on long-term fluoxetine treatment: response to increased fluoxetine dose. Feb 52–55
**Fawcett J.** Compliance: definitions and key issues. Suppl 1, 4–10
**Fawcett J, Marcus RN, Anton SF, O'Brien K, Schwiderski U.** Response of anxiety and agitation symptoms during nefazodone treatment of major depression. Suppl 6, 37–42
**Fawcett J see Carter CS; Zajecka JM**
**Feder R.** Clonidine treatment of excessive sweating [letter]. Jan 35
**Feighner JP.** Cardiovascular safety in depressed patients: focus on venlafaxine. Dec 574–579
**Feighner JP see Ascher JA**
**Fernandez F, Levy JK, Lachar BL, Small GW.** Management of depression and anxiety in the elderly. Suppl 2, 20–29
**Ferris RM see Ascher JA**
**Fibiger HC see Ascher JA**
**Firestone D see Buzan RD**
**Fisher S, Kent TA, Bryant SG.** Postmarketing surveillance by patient self-monitoring: preliminary data for sertraline versus fluoxetine. July 288–296
**Fleischmann RL see McDougle CJ**
**Foa EB see Liebowitz MR**
**Foglia JP see Wisner KL**
**Forsyth KM see Sweet RA**
**Fragala MR see Sabaawi M**
**Francis RJ see Mendels J**
**Frank E, Kupfer DJ, Siegel LR.** Alliance not compliance: a philosophy of outpatient care. Suppl 1, 11–17
**Frazier JA see Piscitelli SC**
**Frenkel M see Stein DJ**
**Freudenreich O, McEvoy JP.** Added amantadine may diminish tardive dyskinesia in patients requiring continued neuroleptics [letter]. Apr 173
**Freudenreich O, McEvoy JP.** How much Haldol D does Larry really need? [letter]. July 331–332
**Friedman JH see Rich SS**
**Friedman LM see McElroy SL**
**Fristad MA.** Review of Wilkes TCR, Belsher G, Rush AJ, Frank E: *Cognitive Therapy for Depressed Adolescents.* June 267
**Froehlich JC.** Genetic factors in alcohol self-administration. Suppl 7, 15–23
**Galli VB see Whittier MC**
**Gálvez-Borrero IM see Cano-Muñoz JL**
**Galynker II, Rosenthal RN, Perkel C, Shwartz A.** Doxepin withdrawal mania [letter]. Mar 122–123
**Galynker II see Levinson I**
**Gaufberg E, Ellison JM.** Photosensitivity reaction to fluoxetine [letter]. Oct 486
**Gelenberg AJ.** Editorial: threats and promises. Oct 448–449
**Gelenberg AJ.** Reply to Modell JG: High cost of buspirone [letter]. Aug 376
**Gelenberg AJ, Jefferson JW.** Lithium tremor. July 283–287
**Gelenberg AJ, Ottosson J-O.** Duplicate publication [letter]. Feb 81
**Geçorge TP, Sernyak MJ, Ziedonis DM, Woods SW.** Effects of clozapine on smoking in chronic schizophrenic outpatients. Aug 344–346
**Geracioti TD Jr.** Venlafaxine treatment of panic disorder: a case series. Sept 408–410
**Geraisy N see Silver H**
**Gillin JC see Rapaport MH**
**Giron A see David D**
**Gitlin MJ.** Reply to Jefferson JW: Psychotropic medications and their effects on sexual function [letter]. Nov 537
**Gitlin MJ.** Treatment of sexual side effects with dopaminergic agents [letter]. Mar 124
**Gold DD Jr.** Review of Cromwell RL, Snyder CR (eds): *Schizophrenia: Origins, Processes, Treatment and Outcome.* Feb 84
**Gold DD Jr.** Review of Perris C: *Cognitive Therapy With Schizophrenic Patients.* June 267–268
**Gold DD Jr.** Review of Torrey EF: *Surviving Schizophrenia: A Manual for Families, Consumers and Providers, Third Edition.* Sept 436–437
**Gold R, Lenox RH.** Is there a rationale for iron supplementation in the treatment of akathisia? a review of the evidence. Oct 476–483
**Golden RN see Ascher JA**
**Golshan S see Rapaport MH**
**Goodnick PJ.** Nimodipine treatment of rapid cycling bipolar disorder [letter]. July 330
**Goodnick PJ.** Risperidone treatment of refractory acute mania [letter]. Sept 431–432
**Goodnick PJ, Henry JH, Buki VMV.** Treatment of depression in patients with diabetes mellitus. Apr 128–136
**Gordon CT, Cotelingam GM, Stager S, Ludlow CL, Hamburger SD, Rapoport JL.** Double-blind comparison of clomipramine and desipramine in the treatment of developmental stuttering. June 238–242
**Granek I see Barak Y**
**Greenberg WM.** Plasma clozapine levels and clinical benefit [letter with reply]. Nov 535
**Greenberg WM.** Serum cholesterol levels and suicidality [letter with reply]. Sept 434
**Greenhill LL see Biederman J**
**Greer RA see Evans DL**
**Greist JH.** Diagnosis of social phobia. Suppl 5, 5–12
**Greist JH.** Reply to Liebowitz MR: Interim analysis clarification [letter]. Sept 435
**Griffies WS see Wise MG**
**Grothe DR see Piscitelli SC**
**Guelfi JD, White C, Hackett D, Guichoux JY, Magni G.** Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. Oct 450–458
**Guerra BM see Boutros NN**
**Guichoux JY see Guelfi JD**
**Guimarães FS see Zuardi AW**
**Gupta S see Masand P**
**Guttmacher LB see Maharaj K**
**Hackett D see Guelfi JD**
**Hamburger SD see Gordon CT**
**Hampel H, Putz A, Müller N.** Major depression following myiasis with hypereosinophilic syndrome [letter]. July 333–334
**Hanks DL see Keller MB**
**Harrison W see Brown WA**
**Heimberg RG see Sweet RA**
**Hellweg R see Bak TH**
**Hendrick V see Altshuler LL**
**Henry JH see Goodnick PJ**
**Heon V see Baker J**
**Hertzman M see Carter CS**
**Herzog DB see Brewerton TD**
**Hirschfeld RMA.** Impact of health care reform on social phobia. Suppl 5, 13–17
**Hirschfeld RMA.** Reply to Sherman Y: Depressive personality disorder [letter]. June 266
**Hollander E, Wong CM.** Body dysmorphic disorder, pathological gambling, and sexual compulsions. Suppl 4, 7–13
**Hollander E, Wong CM.** Introduction: obsessive-compulsive spectrum disorders. Suppl 4, 3–6
**Hollander E see Cohen LJ; Simeon D; Stein DJ**

**Hollister LE.** Electrocardiographic screening in psychiatric patients. Jan 26–29
**Holmes TF see Sabaawi M**
**Holt CS see Sweet RA**
**Holtman HM see Keck PE Jr**
**Horne M, Lindley SE.** Divalproex sodium in the treatment of aggressive behavior and dysphoria in patients with organic brain syndromes [letter]. Sept 430–431
**Hourtané M see Lejoyeux M**
**Howanitz E, Pardo M, Losonczy M.** Photosensitivity to clozapine [letter]. Dec 589
**Hudson JI see Phillips KA**
**Hurly E see Berk M**
**Isaacson JH see Schubiner H**
**Islam MN see Stein DJ**
**Ives JR see Weilburg JB**
**Jackson CW see Pitner JK**
**Jacobsen FM.** Risperidone in the treatment of affective illness and obsessive-compulsive disorder. Sept 423–429
**Jacobson BF see Berk M**
**Jefferson JW.** Introduction: unmasking social phobia in the clinical setting. Suppl 5, 3–4
**Jefferson JW.** Just what is a "heterocyclic" antidepressant? [letter]. Sept 433
**Jefferson JW.** Psychotropic medications and their effects on sexual function [letter with reply]. Nov 536–537
**Jefferson JW.** Social phobia: a pharmacologic treatment overview. Suppl 5, 18–24
**Jefferson JW, Thompson TD.** Rhinotillexomania: psychiatric disorder or habit? Feb 56–59
**Jefferson JW see Gelenberg AJ**
**Jeffriess H see Zajecka JM**
**Jenike MA, Rauch SL.** Reply to Beale MD: ECT for OCD [letter]. Feb 81–82
**Jenike MA see Miguel EC**
**Jerrett JG, Steffens DC.** Carbon monoxide–related organic mood disorder successfully treated with ECT [letter]. July 332–333
**Jeste DV see Zisook S**
**Jones W see Carter CS**
**Judd LL see Rapaport MH**
**Kahn D see Pine DS**
**Kando JC see Zarate CA Jr**
**Kaplan DS see Masand P**
**Keck PE Jr, Wilson DR, Strakowski SM, McElroy SL, Kizer DL, Balistreri TM, Holtman HM, DePreist M.** Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders. Oct 466–470
**Keck PE Jr see McElroy SL**
**Keitner GI see Solomon DA**
**Keller MB, Hanks DL.** Anxiety symptom relief in depression treatment outcomes. Suppl 6, 22–29
**Keller MB see Solomon DA**
**Kellner CH see Beale MD**
**Kelsoe JR Jr see Rapaport MH**
**Kennedy CL.** Review of Gaw AC (ed): *Culture, Ethnicity and Mental Illness.* Jan 40
**Kent TA see Fisher S**
**Ketter TA, Post RM, Parekh PI, Worthington K.** Addition of monoamine oxidase inhibitors to carbamazepine: preliminary evidence of safety and antidepressant efficacy in treatment-resistant depression. Oct 471–475
**Kizer DL see Keck PE Jr**
**Kline MD see Masand P**
**Kornreich C, Den Dulk A, Verbanck P, Pelc I.** Fluoxetine treatment of compulsive masturbation in a schizophrenic patient [letter]. July 334
**Kozak MJ see Liebowitz MR**
**Kreider MS, Bushnell WD, Oakes R, Wheadon DE.** Double-blind, randomized study to provide safety information on switching fluoxetine-treated patients to paroxetine without an intervening washout period. Apr 142–145
**Kuck J see Zisook S**
**Kupfer DJ.** Introduction: compliance strategies to optimize antidepressant treatment outcomes. Suppl 1, 3
**Kupfer DJ see Frank E**
**Kurit DM see Althof SE**
**Labbate LA see Fava M**
**Lachar BL see Fernandez F**
**Lamberti JS, Bellnier TJ, Schwarzkopf SB, Schneider E.** Filgrastim treatment of three patients with clozapine-induced agranulocytosis. June 256–259
**Lange SC see Nichol MB**
**Leckman JF see McDougle CJ**
**Lejoyeux M, Hourtané M, Adès J.** Compulsive buying and depression [letter]. Jan 38
**Lemke MR.** Effect of carbamazepine on agitation in Alzheimer's inpatients refractory to neuroleptics. Aug 354–357
**Lenox RH see Gold R**
**Leong GB see Silva JA**
**Levine SB see Althof SE**
**Levinson I, Galynker II, Rosenthal RN.** Methadone withdrawal psychosis. Feb 73–76
**Levy D see Barak Y**
**Levy JK see Fernandez F**
**Liebowitz M see Carter CS**
**Liebowitz MR, Foa EB, Kozak MJ.** Interim analysis clarification [letter with reply]. Sept 435
**Linder HF.** Review of Guttmacher LB: *Concise Guide to Psychopharmacology and Electroconvulsive Therapy.* Mar 125
**Lindley SE see Horne M**
**Losonczy M see Howanitz E**
**Lonczak HS see Strakowski SM**
**Ludlow CL see Gordon CT**
**Lydiard RB see Brewerton TD**
**Lynch CF see Philibert RA**
**Mackenzie TB see Christenson GA**
**MacQueen GM see Rosebush PI**
**Maddock RJ see Carter CS**
**Madhusoodanan S, Brenner R, Araujo L, Abaza A.** Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: a case series. Nov 514–518
**Magni G see Guelfi JD**
**Maharaj K, Guttmacher LB, Moeller R.** Haloperidol decanoate: injection site reactions [letter]. Apr 172–173
**Maina G see Ravizza L**
**Malek-Ahmadi P, Allen SA.** Paroxetine-molindone interaction [letter]. Feb 82–83
**Mann SC see McCall WV**
**Marcus RN see Fawcett J; Mendels J; Rickels K**
**Margo KL see Masand P**
**Marks IM.** Advances in behavioral-cognitive therapy of social phobia. Suppl 5, 25–31
**Martin P see Ascher JA**
**Martindale JJ see Bennie EH**
**Masand PS, Kaplan DS, Gupta S, Bhandary AN, Nasra GS, Kline MD, Margo KL.** Major depression and irritable bowel syndrome: is there a relationship? Aug 363–367
**Mazure CM, Cellar JS, Bowers MB Jr, Nelson JC, Takeshita J, Zigun B.** Assessment of extrapyramidal symptoms during acute neuroleptic treatment. Mar 94–100
**Mazurek MF see Rosebush PI**
**McCall WV, Mann SC, Shelp FE, Caroff SN.** Fatal pulmonary embolism in the catatonic syndrome: two case reports and a literature review. Jan 21–25
**McDougle CJ, Fleischmann RL, Epperson CN, Wasylink S, Leckman JF, Price LH.** Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases. Nov 526–528
**McElroy SL, Keck PE Jr, Friedman LM.** Minimizing and managing antidepressant side effects. Suppl 2, 49–55
**McElroy SL, Keck PE Jr, Phillips KA.** Kleptomania, compulsive buying, and binge-eating disorder. Suppl 4, 14–27
**McElroy SL see Bowden CL; Keck PE Jr; Phillips KA**
**McEvoy JP see Freudenreich O**
**McGrath PJ see Nunes EV**
**McMullen M see Altshuler LL**
**Mechoulam R see Zuardi AW**
**Meckler L see Narayan M**
**Mehta R see Strakowski SM**
**Mellman TA see David D**
**Mendels J.** Sertraline for premature ejaculation [letter with reply]. Dec 591
**Mendels J, Reimherr F, Marcus RN, Roberts DL, Francis RJ, Anton SF.** Double-blind, placebo-controlled trial of two dose ranges of nefazodone in the treatment of depressed outpatients. Suppl 6, 30–36
**Michels R.** Commentary. Medication use during psychoanalysis: a survey. May 179
**Miguel EC, Coffey BJ, Baer L, Savage CR, Rauch SL, Jenike MA.** Phenomenology of intentional repetitive behaviors in obsessive-compulsive disorder and Tourette's disorder. June 246–255
**Miller IW see Solomon DA**
**Mintzer JE see Pitner JK**
**Mirin J see Zarate CA Jr**
**Modai I, Valevski A, Weizman A.** Reply to Greenberg WM: Serum cholesterol levels and suicidality [letter]. Sept 434–435
**Modell JG.** High cost of buspirone [letter with reply]. Aug 375–376
**Moeller R see Maharaj K**
**Moldawsky RJ.** Role for stimulants in the treatment of depressive disorders [letter with reply]. Aug 376
**Montejo-Iglesias ML see Cano-Muñoz JL**
**Morais SL see Zuardi AW**
**Müller N see Hampel H**
**Mullin JM see Bennie EH**
**Mullins UL see Taylor DP**
**Muñoz RA.** Review of Schorr JH, Scheiber SC (eds): *Certification, Recertification, and Lifetime Learning in Psychiatry.* Jan 40
**Murphy GE.** In memoriam: Eli Robins, M.D. (1921–1994). June 228
**Musial J see Schubiner H**
**Najara JE, Enikeev ID.** Risperidone and neuroleptic malignant syndrome: a case report [letter]. Nov 534–535
**Narayan M, Meckler L, Nelson JC.** Fluoxetine-induced delusions in psychotic depression [letter]. July 329
**Nasra GS see Masand P**

**Nelson JC, Roth A.** Reply to Rothschild AJ: Delirium: an SSRI-benztropine adverse effect? [letter]. Nov 537
**Nelson JC see Mazure CM; Narayan M**
**Newhouse RG.** Review of Feldman MD, Ford CV: *Patient or Pretender.* Mar 125
**Newhouse RG.** Review of Kennedy SH (ed): *Clinical Advances in Monoamine Oxidase Inhibitors.* Mar 125
**Newhouse RG.** Review of Leonard BE: *Fundamentals of Psychopharmacology.* May 213
**Newhouse RG.** Review of Murburg MM (ed): *Catecholamine Function in Posttraumatic Stress Disorder.* Apr 174
**Neylan TC.** Treatment of sleep disturbances in depressed patients. Suppl 2, 56–61
**Nichol MB, Stimmel GL, Lange SC.** Factors predicting the use of multiple psychotropic medications. Feb 60–66
**Nierenberg AA see Fava M**
**Nozaki S see Terao T**
**Nunes EV, McGrath PJ, Quitkin FM.** Treating anxiety in patients with alcoholism. Suppl 2, 3–9
**O'Brien CP see Volpicelli JR**
**O'Brien K see Fawcett J**
**O'Neil PM see Brewerton TD**
**O'Malley SS.** Integration of opioid antagonists and psychosocial therapy in the treatment of narcotic and alcohol dependence. Suppl 7, 30–38
**Oakes R see Kreider MS**
**Oga T see Terao T**
**Ogilvy CS see Tatter SB**
**Okada M see Terao T**
**Ota A see Terao T**
**Ott BR see Rich SS**
**Ottosson J-O see Gelenberg AJ**
**Otsubo Y see Terao T**
**Pajer K.** New strategies in the treatment of depression in women. Suppl 2, 30–37
**Papp LA see Carter CS**
**Pardo M see Howanitz E**
**Parekh PI see Ketter TA**
**Patterson WM see Carter CS**
**Pava JA see Fava M**
**Paykel ES.** Psychotherapy, medication combinations, and compliance. Suppl 1, 24–30
**Pelc I see Kornreich C**
**Pennypacker LC see Pitner JK**
**Perel JM see Wisner KL**
**Perkel C see Galynker II**
**Peterson JM see Bell IR**
**Philibert RA, Richards L, Lynch CF, Winokur G.** Effect of ECT on mortality and clinical outcome in geriatric unipolar depression. Sept 390–394
**Phillips KA, McElroy SL, Hudson JI, Pope HG Jr.** Body dysmorphic disorder: an obsessive-compulsive spectrum disorder, a form of affective spectrum disorder, or both? Suppl 4, 41–52
**Phillips KA see McElroy SL**
**Pies RW.** Dose-related sensory distortions with zolpidem [letter]. Jan 35–36
**Pies RW, Popli AP.** Self-injurious behavior: pathophysiology and implications for treatment. Dec 580–588
**Pine DS, Douglas CJ, Charles E, Davies M, Kahn D.** Patients with multiple sclerosis presenting to psychiatric hospitals. July 297–306
**Piscitelli SC, Grothe DR, Frazier JA.** Reply to Greenberg WM: Plasma clozapine levels and clinical benefit [letter]. Nov 535–536
**Pitner JK, Mintzer JE, Pennypacker LC, Jackson CW.** Efficacy and adverse effects of clozapine in four elderly psychotic patients. May 180–185
**Pollack MH see Weilburg JB**
**Pope HG Jr see Phillips KA**
**Popkin MK.** Commentary: patients with multiple sclerosis presenting to psychiatric hospitals. July 307–308
**Popli AP see Pies RW**
**Post RM see Ketter TA**
**Potter WZ see Ascher JA**
**Preskorn SH.** Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. Suppl 6, 12–21
**Price LH see McDougle CJ**
**Pritchett JT see Beale MD**
**Putz A see Hampel H**
**Quitkin FM see Nunes EV**
**Rank DH.** Subsyndromal symptomatic depression may include sleep disorders [letter]. July 329
**Rapaport MH, Thompson PM, Kelsoe JR Jr, Golshan S, Judd LL, Gillin JC.** Gender differences in outpatient research subjects with affective disorders: a comparison of descriptive variables. Feb 67–72
**Rapoport JL see Gordon CT**
**Rappe SM see Fava M**
**Rauch SL see Jenike MA; Miguel EC**
**Raute NJ see Whittier MC**
**Ravizza L, Barzega G, Bellino S, Bogetto F, Maina G.** Predictors of drug treatment response in obsessive-compulsive disorder. Aug 368–373
**Reimherr F see Mendels J**
**Reischies FM see Bak TH**
**Remington GJ.** Love without romance: the complexity of erotomanic delusions [letter]. Nov 533–534
**Remington ND see Chung CK**
**Rich SS, Friedman JH, Ott BR.** Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. Dec 556–559
**Richards L see Philibert RA**
**Richelson E see Ascher JA**
**Rickels K, Robinson DS, Schweizer E, Marcus RN, Roberts DL.** Nefazodone: aspects of efficacy. Suppl 6, 43–46
**Ries R see Tsuang D**
**Ring A see Barak Y**
**Risen CB see Althof SE**
**Roberts DL see Mendels J; Rickels K**
**Roberts JM see Brady KT**
**Robertson MM, Eapen V, van de Wetering BJM.** Suicide in Gilles de la Tourette's syndrome: report of two cases [letter]. Aug 378
**Robinson DS see Rickels K**
**Roose SP see Donovan SJ**
**Rosebush PI, MacQueen GM, Clarke JTR, Callahan JW, Strasberg PM, Mazurek MF.** Late-onset Tay-Sachs disease presenting as catatonic schizophrenia: diagnostic and treatment issues. Aug 347–353
**Rosen J see Cohen LJ**
**Rosenbaum JF see Fava M**
**Rosenthal RH.** Review of Zerbe KJ: *The Body Betrayed—Women, Eating Disorders, and Treatment.* Jan 39–40
**Rosenthal RN see Galynker II; Levinson I**
**Ross JS see Zajecka JM**
**Roth A see Nelson JC**
**Rothschild AJ.** Delirium: an SSRI-benztropine adverse effect? [letter with reply]. Nov 537
**Roy-Byrne PP see Tsuang D**
**Ruiz-Rodriguez R see Baker J**
**Ryan ND see Biederman J**
**Sabaawi M, Holmes TF, Fragala MR.** Reply to Moldawsky RJ: Role for stimulants in the treatment of depressive disorders [letter]. Aug 376–377
**Sachs GS see Weilburg JB**
**Salzman C.** Medication compliance in the elderly. Suppl 1, 18–23
**Saravay SM see Tejera CA**
**Savage CR see Miguel EC**
**Sax KW see Strakowski SM**
**Scanga DM see Sweet RA**
**Schachter S see Weilburg JB**
**Schaub RT see Bak TH**
**Schneider E see Lamberti JS**
**Schomer DL see Weilburg JB**
**Schubiner H, Tzelepis A, Isaacson JH, Warbasse LH III, Zacharek M, Musial J.** Dual diagnosis of attention-deficit/hyperactivity disorder and substance abuse: case reports and literature review. Apr 146–150
**Schwartz GE see Bell IR**
**Schwartz M, Weller B, Erdreich M, Sharf B.** Rabbit syndrome and tardive dyskinesia: two complications of chronic neuroleptic treatment [letter]. May 212
**Schwartz M see Silver H**
**Schwarzkopf SB see Lamberti JS**
**Schweizer E see Rickels K**
**Schwiderski U see Fawcett J**
**Scott AM.** Review of Bloch S, Hafner J, Harari E, Szmukler GI: *The Family in Clinical Psychiatry.* Dec 592
**Segraves KB see Segraves RT**
**Segraves RT, Segraves KB, Bubna CN.** Sexual function in patients taking bupropion sustained release [letter]. Aug 374
**Sernyak MJ see George TP**
**Sharf B see Schwartz M**
**Shea MT see Solomon DA**
**Sheline YI see Black KJ**
**Shelp FE see McCall WV**
**Sherman Y.** Depressive personality disorder [letter with reply]. June 266
**Sholomskas DE, Wickamaratne PJ, Woods SW.** Reply to Benjamin J: Panic disorder and pregnancy [letter]. Jan 36
**Shwartz A see Galynker II**
**Siegel LR see Frank E**
**Silva JA, Tekell JL, Leong GB, Bowden CL.** Delusional misidentification of the self associated with nondominant cerebral pathology [letter]. Apr 171
**Silver H, Geraisy N, Schwartz M.** No difference in the effect of biperiden and amantadine on parkinsonian– and tardive dyskinesia–type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients. Apr 167–170; correction Sept 435
**Simeon D, Stein DJ, Hollander E.** Depersonalization disorder and self-injurious behavior. Suppl 4, 36–40
**Simeon D see Cohen LJ; Stein DJ**
**Small GW see Fernandez F**
**Smith HL see Taylor DP**
**Smith S see Boutros NN**
**Solomon DA, Keitner GI, Miller IW, Shea MT, Keller MB.** Course of illness and maintenance

treatments for patients with bipolar disorder. Jan 5–13
**Sonne SC see Brady KT**
**Spadaccini E see Cohen LJ**
**Srivastava M see Abbas S**
**Stager S see Gordon CT**
**Steffens DC see Jerrett JG**
**Stein DJ, Hollander E.** Obsessive-compulsive spectrum disorders [letter]. June 265–266
**Stein DJ, Simeon D, Cohen LJ, Hollander E.** Trichotillomania and obsessive-compulsive disorder. Suppl 4, 28–35
**Stein DJ, Simeon D, Frenkel M, Islam MN, Hollander E.** Open trial of valproate in borderline personality disorder. Nov 506–510
**Stein DJ see Cohen LJ; Simeon D**
**Steingard S see Vasile JS**
**Stern EB see Althof SE**
**Sternbach H.** Fluoxetine-clomipramine interaction [letter]. Apr 171–172
**Stimmel GL see Nichol MB**
**Strakowski SM, Lonczak HS, Sax KW, West SA, Crist A, Mehta R, Thienhaus OJ.** Effects of race on diagnosis and disposition from a psychiatric emergency service. Mar 101–107
**Strakowski SM see Keck PE Jr**
**Strasberg PM see Rosebush PI**
**Suh BY see Chung CK**
**Sulser F see Ascher JA**
**Surawicz FG.** Review of Mirkin MP (ed): *Women in Context: Toward a Feminist Reconstruction of Psychotherapy.* July 335
**Swann AC.** Mixed or dysphoric manic states: psychopathology and treatment. Suppl 3, 6–10
**Sweet RA, Brown EJ, Heimberg RG, Ciafre L, Scanga DM, Cornelius JR, Dube S, Forsyth KM, Holt CS.** Monoamine oxidase inhibitor dietary restrictions: what are we asking patients to give up? May 196–201
**Swift RM.** Effect of naltrexone on human alcohol consumption. Suppl 7, 24–29
**Swinson RP see Carter CS**
**Szabo CP.** Fluoxetine and sumatriptan: possibly a counterproductive combination [letter]. Jan 37–38
**Szor H see Barak Y**
**Takeshita J see Mazure CM**
**Tatter SB, Ogilvy CS.** Recurrent manic episode 10 years after arteriovenous malformation resection [letter]. Feb 83
**Taylor DP, Carter RB, Eison AS, Mullins UL, Smith HL, Torrente JR, Wright RN, Yocca FD.** Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug. Suppl 6, 3–11
**Tejera CA, Saravay SM.** Treatment of organic personality syndrome with low-dose trazodone [letter]. Aug 374–375
**Tekell JL see Silva JA**
**Terao T, Oga T, Nozaki S, Ota A, Otsubo Y, Yamamoto S, Zamami M, Okada M.** Further prospective evaluation of an equation to predict daily lithium dose. May 193–195
**Thienhaus OJ see Strakowski SM**
**Thisted RA see Biederman J**
**Thomas M see Buzan RD; Dubovsky SL**
**Thompson PM see Rapaport MH**
**Thompson TD see Jefferson JW**
**Toews JA see Addington DE**
**Tohen M see Zarate CA Jr**
**Torrente JR see Taylor DP**
**Tsuang D, Cowley D, Ries R, Dunner DL, Roy-Byrne PP.** Effects of substance use disorder on the clinical presentation of anxiety and depression in an outpatient psychiatric clinic. Dec 549–555
**Tzelepis A see Schubiner H**
**Ulm RR, Volpicelli JR, Volpicelli LA.** Opiates and alcohol self-administration in animals. Suppl 7, 5–14
**Valevski A see Modai I**
**van de Wetering BJM see Robertson MM**
**Vasile JS, Steingard S.** Clozapine and the development of salivary gland swelling: a case study. Nov 511–513
**Verbanck P see Kornreich C**
**Volpicelli JR, Clay KL, Watson NT, O'Brien CP.** Naltrexone in the treatment of alcoholism: predicting response to naltrexone. Suppl 7, 39–44
**Volpicelli JR, O'Brien CP.** Introduction: opioid involvement in alcohol dependence. Suppl 7, 3–4
**Volpicelli JR see Ulm RR**
**Volpicelli LA see Ulm RR**
**Votolato NA see Boutros NN**
**Walker PW.** Review of Stoudemire A (ed): *Psychological Factors Affecting Medical Conditions.* Oct 487
**Walker PW.** Review of Winegar N, Bestline JL: *Marketing Mental Health Services to Managed Care.* Feb 84
**Warbasse LH III see Schubiner H**
**Wasylink S see McDougle CJ**
**Watson NT see Volpicelli JR**
**Weilburg JB, Schachter S, Worth J, Pollack MH, Sachs GS, Ives JR, Schomer DL.** EEG abnormalities in patients with atypical panic attacks. Aug 358–362
**Weise CC see Carter CS**
**Weise RE.** Review of Buckman ES (ed): *The Handbook of Humor: Clinical Applications in Psychotherapy.* June 267
**Weiss MK see Zarate CA Jr**
**Weizman A see Aizenberg D; Modai I**
**Weller B see Schwartz M**
**West SA see Strakowski SM; Whittier MC**
**Wheadon DE see Kreider MS**
**White C see Guelfi JD**
**Whitfeld M see Baker J**
**Whittier MC, West SA, Galli VB, Raute NJ.** Valproic acid for dysphoric mania in a mentally retarded adolescent [letter]. Dec 590–591
**Wickamaratne PJ see Sholomskas DE**
**Wilkinson CJ.** Acute effects of zolpidem, administered alone and with alcohol, on cognitive and psychomotor function. July 309–318
**Wilson DR see Keck PE Jr**
**Winokur G see Philibert RA**
**Wise MG, Griffies WS.** Combined treatment approach to anxiety in the medically ill. Suppl 2, 14–19
**Wise TN.** Reply to Mendels: Sertraline for premature ejaculation [letter]. Dec 591
**Wisner KL, Perel JM, Foglia JP.** Serum clomipramine and metabolite levels in four nursing mother-infant pairs. Jan 17–20
**Wong CM see Hollander E**
**Woods SW see George TP; Sholomskas DE**
**Worth J see Weilburg JB**
**Worthington K see Ketter TA**
**Woyshville MJ see Calabrese JR**
**Wright RN see Taylor DP**
**Yamamoto S see Terao T**
**Yañez-Saez RM see Cano-Muñoz JL**
**Yocca FD see Taylor DP**
**Zacharek M see Schubiner H**
**Zajecka JM, Jeffriess H, Fawcett J.** Efficacy of fluoxetine combined with a heterocyclic antidepressant in treatment-resistant depression: a retrospective analysis. Aug 338–343
**Zajecka JM, Ross JS.** Management of comorbid anxiety and depression. Suppl 2, 10–13
**Zamami M see Terao T**
**Zarate CA Jr, Tohen M, Baldessarini RJ.** Clozapine in severe mood disorders. Sept 411–417
**Zarate CA Jr, Tohen M, Banov MD, Weiss MK, Cole JO.** Is clozapine a mood stabilizer? Mar 108–112
**Zarate CA Jr, Tohen M, Baraibar G, Kando JC, Mirin J.** Prescribing trends of antidepressants in bipolar depression. June 260–264
**Zemishlany Z see Aizenberg D**
**Ziedonis DM see George TP**
**Zigun B see Mazure CM**
**Zisook S, Byrd D, Kuck J, Jeste DV.** Command hallucinations in outpatients with schizophrenia. Oct 462–465
**Zuardi AW, Morais SL, Guimarães FS, Mechoulam R.** Antipsychotic effect of cannabidiol [letter]. Oct 485–486